secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108898
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead
--------------------------------------------------------------------------------

- Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.
- Net loss $18.4M ($0.30 per share) vs $17.3M ($0.29) in prior year; adjusted loss $15.3M.
- Cash, cash equivalents and short-term investments $90.4M; runway into H2 2026.
- Preliminary MICVO monotherapy data in 2L/3L HNSCC expected H2 2025; combination with pembrolizumab data also H2 2025.
- R&D expenses rose to $17.1M, driven by increased MICVO manufacturing and trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025108898/0000950170-25-108898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017025108898/pyxs-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer